

NOTE: This order is nonprecedential.

**United States Court of Appeals  
for the Federal Circuit**

---

**AMGEN INC.,**  
*Plaintiff-Appellant*

v.

**WATSON LABORATORIES, INC., ACTAVIS  
PHARMA, INC.,**  
*Defendants-Appellees*

**CIPLA LIMITED, CIPLA USA INC.,**  
*Defendants-Amici Curiae*

**AMNEAL PHARMACEUTICALS LLC, AMNEAL  
PHARMACEUTICALS OF NEW YORK LLC, CADILA  
HEALTHCARE LTD., DBA ZYDUS CADILA,  
PIRAMAL HEALTHCARE UK LIMITED, SUN  
PHARMA GLOBAL FZE, SUN PHARMACEUTICAL  
INDUSTRIES, INC., SUN PHARMACEUTICAL  
INDUSTRIES, LTD., ZYDUS PHARMACEUTICALS  
(USA) INC.,**  
*Defendants*

---

2019-1650, 2019-1770

---

Appeals from the United States District Court for the District of Delaware in Nos. 1:16-cv-00853-MSG, 1:16-cv-00855-MSG, 1:16-cv-00925-MSG, 1:17-cv-00183-MSG, 1:17-cv-00713-MSG, Judge Mitchell S. Goldberg.

2

AMGEN INC. v. WATSON LABORATORIES, INC.

---

**ON MOTION**

---

Before NEWMAN, LOURIE, and O'MALLEY, *Circuit Judges*.

PER CURIAM.

**O R D E R**

The parties jointly move to voluntarily dismiss the above-captioned appeals pursuant to Fed. R. App. P. 42(b), with each side bearing its own fees and costs.

Upon consideration thereof,

IT IS ORDERED THAT:

The motion is granted.

FOR THE COURT

July 9, 2020  
Date

/s/ Peter R. Marksteiner  
Peter R. Marksteiner  
Clerk of Court

ISSUED AS A MANDATE: July 9, 2020